Merck to boost Gardasil production; Increased demand for Sanofi’s RSV drug; Takeda addresses facility ‘impairment’
Endpoints News looked into earnings call transcripts to find information nuggets on biopharma manufacturing plans. We discovered that Merck and Sanofi are both aiming to manage market demand, while Takeda and Novartis are trying to address manufacturing constraints and access.
Merck is ramping up manufacturing capacity at two facilities to increase production of its HPV vaccine Gardasil, despite speculating slower demand in the later half of this year on its second-quarter call a few months ago. “We’ve made significant investments in manufacturing capacity and from that perspective, now we’re well positioned,” CEO Robert Davis told investors on Thursday, according to an AlphaSense transcript. Merck touted a boost in sales of Gardasil during the second quarter, saying they reached $2.5 billion — up 47% from the same three months of last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.